Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a cream for topical use. It is authorized in the European Union for this indication and is supplied by prescription only. It is employed in the management of actinic keratosis affecting the face and scalp, primarily in adult patients with sun‑damage‑related skin lesions.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulatory‑approved batches and supporting import documentation for global distribution.

Metvix (methyl aminolevulinate) is a topical photosensitizer used in the treatment of actinic keratosis, a precancerous skin condition caused by ultraviolet damage. - Actinic keratosis of the face: clears dysplastic lesions and reduces risk of progression to squamous cell carcinoma. - Actinic keratosis of the scalp: removes precancerous spots and improves skin appearance. - Field cancerization on sun‑exposed areas: treats multiple lesions within a defined treatment field.

Common Side Effects: - Erythema: redness at the application site. - Edema: localized swelling. - Pain or burning sensation during illumination. - Crusting and desquamation as the treated area heals.

Serious or Rare Side Effects: - Severe photosensitivity reactions extending beyond the treated area. - Secondary infection of the treated skin. - Allergic contact dermatitis to the cream components. - Scarring or pigmentary changes. - Ocular damage if light exposure occurs to the eyes.

Metvix should be used only under medical supervision with appropriate patient selection. - Patient selection: prescribe for adults with confirmed actinic keratosis. - Sun exposure: avoid direct sunlight on treated area for the recommended post‑treatment period. - Eye protection: wear protective goggles during illumination to prevent ocular injury. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Storage: Store at room temperature below 25°C: keep in original packaging, protect from moisture and light.

Methyl aminolevulinate may interact with other agents that affect photosensitivity.

Major Interactions (Avoid): - Systemic photosensitizers (e.g., tetracyclines, retinoids): increase risk of severe phototoxic reactions. - Concurrent photodynamic therapy agents: may cause overlapping toxicity.

Moderate Interactions (Monitor Closely): - Topical corticosteroids applied before illumination: may reduce efficacy. - Anticoagulants: monitor for bleeding if extensive skin injury occurs. - Immunosuppressants: may alter healing response and increase infection risk.